,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2016-07-07 05:20:00,"According to a recent study conducted by Bank of America /Merrill Lynch, growth stocks and value stocks have both been solid performers since 1926, with growth stocks up an average of 12.6% and value stocks up 17%.",0.94340580701828,0.022555984556674957,0.0340382382273674,positive,0.9208498001098633
1,2016-07-07 05:20:00,"However, the study also notes that growth has been handily outperforming value of late, which is probably a reaction to lending rates that have remained near historic lows and companies that have cheap and ready access to capital that they can use to expand.",0.8945316076278687,0.045464836061000824,0.06000345200300217,positive,0.8490667939186096
2,2016-07-07 05:20:00,The implication is simple: This could be growth stocks' time to shine.,0.0572105348110199,0.022036457434296608,0.9207530617713928,neutral,0.03517407923936844
3,2016-07-07 05:20:00,So what growth stocks should you have on your radar?,0.036709897220134735,0.017271308228373528,0.9460188150405884,neutral,0.019438588991761208
4,2016-07-07 05:20:00,"We posed this very question to three of our contributors, and the following three growth stocks ranked high on their list of must-watch companies.",0.42495447397232056,0.014434345066547394,0.5606111884117126,neutral,0.41052013635635376
5,2016-07-07 05:20:00,"Sean Williams: If you like growth, you'll struggle to find a company that can deliver it more consistently than biotech blue chip Celgene (NASDAQ: CELG) , which has three primary methods of growth.",0.5096984505653381,0.023347798734903336,0.46695369482040405,positive,0.4863506555557251
6,2016-07-07 05:20:00,"First, Celgene can grow the most traditional way possible: organically.",0.5399044752120972,0.008928218856453896,0.4511672556400299,positive,0.5309762358665466
7,2016-07-07 05:20:00,"Celgene's main organic growth driver is Revlimid, the premier first- and second-line multiple myeloma therapy.",0.4747321903705597,0.008772180415689945,0.5164956450462341,neutral,0.46595999598503113
8,2016-07-07 05:20:00,"Celgene is benefiting from a growing number of multiple myeloma diagnoses, longer treatment timeframes, and pricing power.",0.8813585042953491,0.012425899505615234,0.10621567815542221,positive,0.8689326047897339
9,2016-07-07 05:20:00,"Adding more fuel to the fire, Celgene also reached an agreement with generic-drug distributors regarding the entrance of generic Revlimid into the market.",0.9308974146842957,0.0184869933873415,0.05061556026339531,positive,0.9124104380607605
10,2016-07-07 05:20:00,"Under the terms of the deal, only Natco Pharma will be able to sell a limited supply of generic Revlimid beginning in March 2022, but a full-fledged generic flood isn't going to occur until January 2026.",0.17631587386131287,0.01745649240911007,0.8062276244163513,neutral,0.15885938704013824
11,2016-07-07 05:20:00,This means Revlimid is set up to become a cash cow for the next decade.,0.5634589791297913,0.010570728220045567,0.4259703457355499,positive,0.5528882741928101
12,2016-07-07 05:20:00,Sales of Celgene's key drug have been growing at between 15% and 20% per year.,0.8669973611831665,0.013665459118783474,0.11933712661266327,positive,0.8533319234848022
13,2016-07-07 05:20:00,"Secondly, Celgene can grow inorganically by means of acquisitions.",0.4415522813796997,0.007744168862700462,0.5507035255432129,neutral,0.4338081181049347
14,2016-07-07 05:20:00,"For example, in 2010 it acquired Abraxis BioScience in order to get ahold of metastatic breast cancer drug Abraxane, which had $315 million in sales in 2009.",0.5444837212562561,0.010976649820804596,0.4445396065711975,positive,0.5335070490837097
15,2016-07-07 05:20:00,"In the subsequent years following the purchase, Abraxane's label was expanded to advanced pancreatic cancer and advanced non-small-cell lung cancer (NSCLC).",0.5092065930366516,0.009016343392431736,0.4817770719528198,positive,0.500190258026123
16,2016-07-07 05:20:00,"This year, Abraxane sales could touch $1 billion, even though they've been slowed a bit by the emergence of cancer immunotherapies in advanced solid tumor diseases such as NSCLC.",0.1387525498867035,0.802216649055481,0.05903078243136406,negative,-0.6634640693664551
17,2016-07-07 05:20:00,"Celgene's new hope rest with its $7.2 billion buyout of Receptos, which allowed it to gain hold of ozanimod, a next-generation multiple sclerosis and ulcerative colitis medicine with $4 billion to $6 billion in peak annual sales potential.",0.913599967956543,0.013338591903448105,0.0730615109205246,positive,0.900261402130127
18,2016-07-07 05:20:00,"Finally, Celgene can use collaborations to its advantage.",0.7886955738067627,0.012332150712609291,0.19897232949733734,positive,0.7763634324073792
19,2016-07-07 05:20:00,"Celgene understands that it can't be everywhere at once, so it's leveraging its R&D by partnering with more than 30 different drug developers to discover first-in-class treatments for cancer, immunology, and inflammation.",0.7915413975715637,0.01136176846921444,0.1970967948436737,positive,0.7801796197891235
20,2016-07-07 05:20:00,"If Celgene sees promising data, it can choose to fully license the developing product.",0.4695487320423126,0.008621148765087128,0.521830141544342,neutral,0.4609275758266449
21,2016-07-07 05:20:00,Being a collaboration-heavy company means putting its resources toward only the most promising pipeline products.,0.13211794197559357,0.007099106442183256,0.8607829809188843,neutral,0.12501883506774902
22,2016-07-07 05:20:00,"Looking ahead, Celgene anticipates its 2020 sales will exceed $21 billion, and that its full-year EPS will eclipse $13.",0.5752614140510559,0.01150358747690916,0.41323503851890564,positive,0.5637578368186951
23,2016-07-07 05:20:00,"By comparison, Celgene's fiscal 2015 generated only $9.26 billion in sales and $4.71 in adjusted EPS.",0.02993079088628292,0.2803688943386078,0.6897003054618835,neutral,-0.2504380941390991
24,2016-07-07 05:20:00,"Pretty much, we're looking at a better than doubling in sales and a near-tripling in profits over the next five years.",0.9107041358947754,0.015480692498385906,0.07381515204906464,positive,0.8952234387397766
25,2016-07-07 05:20:00,That's the type of growth investor should be salivating over!,0.18167954683303833,0.019297108054161072,0.7990233302116394,neutral,0.16238243877887726
26,2016-07-07 05:20:00,"Matt DiLallo : The oil market is in its deepest downturn since Ronald Reagan was president, but that hasn't fazed Pioneer Natural Resources (NYSE: PXD) one bit.",0.027643738314509392,0.9270939826965332,0.045262306928634644,negative,-0.8994502425193787
27,2016-07-07 05:20:00,"While most of its peers are just trying to keep their oil production flat this year, Pioneer is planning for double-digit growth.",0.919212281703949,0.019542967900633812,0.061244796961545944,positive,0.8996692895889282
28,2016-07-07 05:20:00,"Looking back at the three regions, there is no laggard in the bunch.",0.05533890426158905,0.09022843092679977,0.8544326424598694,neutral,-0.034889526665210724
29,2016-07-07 05:20:00,"Consider that during the first quarter of fiscal year 2017, the Americas grew revenue by 27% year over year, Europe did the same, and Asia-Pacific grew at a 28% clip -- and that isn't using constant currency, which would have sent the percentages even higher.",0.7484047412872314,0.027821887284517288,0.22377336025238037,positive,0.7205828428268433
30,2016-07-07 05:20:00,"For the full year, the company is guiding for revenue to jump between 22% and 23% to reach between $8.16 billion and $8.20 billion, and investors shouldn't be surprised if Salesforce tops $10 billion in annual revenue sooner rather than later.",0.935490608215332,0.01882316544651985,0.04568611830472946,positive,0.9166674613952637
31,2016-07-07 05:20:00,"It's not a growth story solely revolving around the top line, either, as the company grew its cash flow 43% during the first quarter compared with the prior year, and its non-GAAP operating margin grew 283 points during the same time, which was its eighth consecutive quarter of year-over-year improvement.",0.95920330286026,0.02101125381886959,0.019785337150096893,positive,0.9381920695304871
32,2016-07-07 05:20:00,"If you like growth, Salesforce is begging you to deep-dive into its products for a better understanding, because it's growth story shouldn't end anytime soon.",0.21822471916675568,0.013905543833971024,0.7678697109222412,neutral,0.20431917905807495
33,2016-07-07 05:20:00,"If you're like most Americans, you're a few years (or more) behind on your retirement savings.",0.05384125933051109,0.10082980990409851,0.8453289270401001,neutral,-0.04698855057358742
34,2016-07-07 05:20:00,"But a handful of little-known ""Social Security secrets"" could help ensure a boost in your retirement income.",0.42587700486183167,0.05124306678771973,0.522879958152771,neutral,0.37463393807411194
35,2016-07-07 05:20:00,"For example: one easy trick could pay you as much as $15,834 more... each year!",0.08638019859790802,0.03199373185634613,0.8816260099411011,neutral,0.05438646674156189
36,2016-07-07 05:20:00,"Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after.",0.35658568143844604,0.011904616840183735,0.6315096616744995,neutral,0.344681054353714
37,2016-07-07 05:20:00,Simply click here to discover how to learn more about these strategies.,0.04130851849913597,0.009173430502414703,0.9495180249214172,neutral,0.03213508799672127
38,2016-07-07 05:20:00,Daniel Miller has no position in any stocks mentioned.,0.011121438816189766,0.05143235623836517,0.9374461770057678,neutral,-0.04031091928482056
39,2016-07-07 05:20:00,Matt DiLallo owns shares of Celgene.,0.015767639502882957,0.011786351911723614,0.9724460244178772,neutral,0.003981287591159344
40,2016-07-07 05:20:00,Sean Williams owns shares of Bank of America.,0.019189128652215004,0.010411524213850498,0.9703993201255798,neutral,0.008777604438364506
41,2016-07-07 05:20:00,The Motley Fool owns shares of and recommends Celgene and Salesforce.com.,0.03257637470960617,0.03046581707894802,0.936957836151123,neutral,0.0021105576306581497
42,2016-07-07 05:20:00,"It also has the following options: short October 2016 $95 puts on Celgene, and recommends Bank of America.",0.015393868088722229,0.02494473196566105,0.9596614241600037,neutral,-0.00955086387693882
43,2016-07-07 05:20:00,Try any of our Foolish newsletter services free for 30 days .,0.02325451746582985,0.013860778883099556,0.9628846645355225,neutral,0.009393738582730293
44,2016-07-07 05:20:00,"We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.",0.7942618727684021,0.015105843544006348,0.19063223898410797,positive,0.7791560292243958
45,2016-07-07 05:20:00,The Motley Fool has a disclosure policy .,0.016547100618481636,0.017303917557001114,0.9661489725112915,neutral,-0.0007568169385194778
46,2016-07-07 05:20:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
